A5085259120- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Gastric Cancer Management and Outcomes
- CNS Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Helicobacter pylori-related gastroenterology studies
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Cutaneous lymphoproliferative disorders research
- Genetic factors in colorectal cancer
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- T-cell and Retrovirus Studies
- Vascular Tumors and Angiosarcomas
- Gastrointestinal Tumor Research and Treatment
- Tumors and Oncological Cases
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Eosinophilic Disorders and Syndromes
- Histiocytic Disorders and Treatments
- Gastrointestinal disorders and treatments
- Galectins and Cancer Biology
- Sarcoma Diagnosis and Treatment
Université Paris-Est Créteil
2013-2024
Lymphoma Study Association
2018-2024
Hôpitaux Universitaires Henri-Mondor
2012-2024
The Lymphoma Academic Research Organisation
2024
Inserm
2013-2023
Institut Mondor de Recherche Biomédicale
2009-2023
Assistance Publique – Hôpitaux de Paris
2012-2021
Hôpital Saint-Louis
2009-2021
Hôpital Albert-Chenevier
2012-2021
Centre Hospitalier Universitaire Henri-Mondor
2007-2021
Purpose Apart from localized gastric disease, there is no consensus on standard initial treatment of mucosa-associated lymphoid tissue lymphoma. The IELSG-19 study (Randomized Trial Chlorambucil Versus Plus Rituximab in MALT Lymphoma) was launched to compare chlorambucil alone versus plus rituximab patients not previously given systemic anticancer therapy. Patients and Methods responding or suitable for local therapy were eligible. In arm A, daily 6 mg/m 2 orally (PO) weeks. Responding those...
MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-cell lymphomas (DLBCLs) and has been associated with poor prognosis many studies. The impact MYC-R on may be influenced by the partner gene (immunoglobulin [IG] or a non-IG gene). We evaluated cohort patients through Lunenburg Lymphoma Biomarker Consortium to validate prognostic significance (single-, double-, triple-hit status) DLBCL within context gene.The study included histologically confirmed morphology derived...
Abstract Purpose: Next-generation sequencing (NGS) has detailed the genomic characterization of diffuse large B-cell lymphoma (DLBCL) by identifying recurrent somatic mutations. We set out to design a clinically feasible NGS panel focusing on genes whose mutations hold potential therapeutic impact. Furthermore, for first time, we evaluated prognostic value these in prospective clinical trials. Experimental Design: A Lymphopanel was designed identify 34 genes, selected according literature...
Purpose To prospectively assess the clinical impact of expert review lymphoma diagnosis in France. Materials and Methods From January 2010 to December 2013, 42,145 samples from patients with newly diagnosed or suspected lymphomas were reviewed, according 2008 WHO classification, real time by experts through Lymphopath Network. Changes between referral classified as major minor their potential on patient care. Results The reviewed comprised 36,920 mature lymphomas, 321 precursor lymphoid...
To date, genomic analyses of hepatocellular carcinoma (HCC) have been limited to early stages obtained from liver resection. We aim describe the profiling HCC advanced stages. analyzed 801 720 patients (410 resections, 137 transplantations, 122 percutaneous ablations, and 52 noncurative) for 190 gene expressions 31 mutations. Forty-one 156 whole exome Barcelona Clinic Liver Cancer (BCLC) 0/A were by whole-exome sequencing. Genomic was correlated with tumor stages, clinical features,...
Angioimmunoblastic T-cell lymphoma (AITL) represents a distinct entity among peripheral lymphomas (PTCLs). The cellular origin of AITL remains unknown, although possible derivation from follicular helper T cells (TFH) has been suggested based on the CD4/Bcl-6 phenotype. It recently shown that expression CXCL13, chemokine critically involved in B-cell migration into germinal centers, is characteristic TFH cells, as compared with other subsets. We CXCL13 29 AITLs, 20 PTCLs, unspecified, 10...
Rare cases of peripheral T-cell lymphomas with follicular growth pattern (PTCL-F) have been recently reported, and their association t(5;9)(q33;q22) involving ITK SYK has suggested. However, the clinicopathologic aspects PTCL-F are poorly described normal cell counterpart this subgroup lymphoma is still unknown. Therefore, we analyzed pathologic, phenotypic, cytogenetic features a series 30 patients (range: 33 to 88 y) that showed histopathologic in at least 1 biopsy (n=30), either initial...
The prognostic value of [(18)F]fluorodeoxyglucose-positron emission tomography (PET), interpreted according to visual criteria, is a matter debate for diffuse large B-cell lymphoma (DLBCL). Moreover, most published studies do not differentiate between patients treated with or without rituximab. We retrospectively investigated the PET performed in DLBCL receiving chemotherapy plus Images were both visually and by computing maximum standardized uptake (SUV(max)) at baseline after two cycles...
Primary mediastinal B‐cell lymphoma (PMBL) is an entity of distinct from the other molecular subtypes diffuse large (DLBCL). We investigated prevalence, specificity, and clinical relevance mutations XPO1 , which encodes a member karyopherin‐β nuclear transporters, in cohort PMBL. PMBL cases defined histologically or by gene expression profiling (GEP) were sequenced mutational status was correlated to genetic characteristics. The also assessed DLBCL, Hodgkin (HL) gray‐zone (MGZL).The...
Purpose:MYD88 mutations, notably the recurrent gain-of-function L265P variant, are a distinguishing feature of activated B-cell like (ABC) diffuse large lymphoma (DLBCL), leading to constitutive NFκB pathway activation. The aim this study was examine distinct genomic profiles MYD88-mutant DLBCL, according presence or other non-L265P MYD88 variants.Experimental Design: A cohort 361 DLBCL cases (94 mutant and 267 wild-type) submitted next-generation sequencing (NGS) focusing on 34 genes...
Background For non–small cell lung cancer (NSCLC), treatment with pembrolizumab is limited to patients tumours expressing PD-L1 assessed by immunohistochemistry (IHC) using the IHC 22C3 pharmDx (Dako, Inc.) companion diagnostic test, on Dako Autostainer Link 48 (ASL48) platform. Optimised protocols are urgently needed for use of antibody concentrate test expression more widely available autostainers. Methods We evaluated in three main commercially autostainers ASL48, BenchMark ULTRA (Ventana...
Abstract Fifty-five cases of t(14;18)− follicular lymphoma (FL) were genetically characterized by targeted sequencing and copy number (CN) arrays. FL predominated in women (M/F 1:2); patients often presented during early clinical stages (71%), had excellent prognoses. Overall, displayed CN alterations (CNAs) gene mutations carried conventional t(14;18)+ (cFL), but with different frequencies. The most frequently mutated was STAT6 (57%) followed CREBBP (49%), TNFRSF14 (39%), KMT2D (27%)....
We report 12 European cases of pyothorax-associated lymphomas occurring 30-67 years following artificial pneumothorax for pleuropulmonar tuberculosis. Eleven patients presented with a localized pleural tumor mass, whereas one patient also had liver involvement. Histologic examination showed diffuse proliferation large lymphoid cells frequent plasmacytoid differentiation (n = 8), expressing CD20 10), CD79a 11), and/or CD138 5) B-cell antigens. Aberrant expression T-cell markers (CD2, CD3,...
Purpose To evaluate the prognostic value of cell origin immunohistochemical markers and BCL2, BCL6, c-MYC translocations in a homogeneous cohort patients with diffuse large B-cell lymphoma (DLBCL) treated rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP). Patients Methods CD20+ DLBCL were enrolled randomized LNH98-5 01-5B Groupe d'Etude des Lymphomes de l'Adulte trials. Paraffin-embedded tumor samples 119 R-CHOP analyzed by immunohistochemistry for CD10,...